BCL2L2
ENSG00000129473
Target class
Other cytosolic protein
Chromosome
14
Approved drugs
0
Clinical candidates (approved and in development)
2
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Target name
- BCL2L2
- Gene name
- BCL2 like 2
- Gene symbol
- BCL2L2
- Protein name
- Bcl-2-like protein 2 (Bcl2-L-2) (Apoptosis regulator Bcl-W)
- KIAA0271
- BCL-W
- PPP1R51
- Gene biotype
- Protein coding
- Gene family
- Protein phosphatase 1 regulatory subunits|BCL2 family
- Target class
- Other cytosolic protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 158.09
- Tissue specificity (Gini)
- 0.252
- Tissue specificity (tau)
- 0.57
- KEGG gene identifiers
- hsa:599
- Protein interaction confidence
- 0.897455
- Protein interaction partners
- 22
- End position
- 23313069
- Start position
- 23298790
- Chromosome
- 14
- Strand
- Forward
- Mitochondrion membrane
- Peripheral membrane protein . Note=Loosely associated with the mitochondrial membrane in healthy cells. During apoptosis, tightly bound to the membrane.
- PubMed 11423909
- PubMed 12952938
- Tissue specificity (tau)
- 0.569778
- Expression inequality (Gini)
- 0.251626
Expression in transcripts per million
- Colon - Sigmoid
- 158.09
- Esophagus - Muscularis
- 134.52
- Brain - Frontal Cortex (BA9)
- 129.35
- Artery - Tibial
- 121.45
- Brain - Spinal cord (cervical c-1)
- 120.56
Expression in transcripts per million
- Colon - Sigmoid158.09
- Esophagus - Muscularis134.52
- Brain - Frontal Cortex (BA9)129.35
- Artery - Tibial121.45
- Brain - Spinal cord (cervical c-1)120.56
- Esophagus - Gastroesophageal Junction119.9
- Brain - Cerebellar Hemisphere110.37
- Brain - Cortex99.95
- Brain - Cerebellum96.9
- Nerve - Tibial96.46
- Brain - Substantia nigra95.36
- Artery - Aorta91.35
- Artery - Coronary89.1
- Uterus88.64
- Brain - Anterior cingulate cortex (BA24)87.72
- Bladder87.05
- Prostate83.29
- Brain - Hypothalamus83.05
- Brain - Amygdala72.52
- Pituitary72.32
- Thyroid72.04
- Skin - Sun Exposed (Lower leg)69.91
- Lung69.77
- Fallopian Tube69.72
- Cervix - Endocervix69.49
And 29 more, listed on the interactive page.
- GO:0007283
- GO:0042981
- GO:0043066
- GO:0005739
- GO:0097136
- GO:0005515
- GO:0042802
- GO:0097718
Related records
Trials (756)
- 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
- a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
- A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
- A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
- A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
- A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia
- A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients
- A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL
- A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
Drugs (6)
- ABT 737
- Navitoclax Apoptosis regulator Bcl-W inhibitor
- Navitoclax dihydrochloride Apoptosis regulator Bcl-W inhibitor
- Obatoclax Apoptosis regulator Bcl-W inhibitor
- Obatoclax mesylate Apoptosis regulator Bcl-W inhibitor
- Venetoclax